OncoMyx Therapeutics
Pharmaceutical ManufacturingArizona, United States2-10 Employees
OncoMyx Therapeutics is a small pharmaceutical company based in Peoria, Arizona, pursuing cancer therapies centred on the myxoma virus (MYXV). The virus is described as highly immunostimulatory and non-pathogenic outside rabbits, and the company advances a systemic delivery approach in which human leukocytes carry the virus to infect tumor cells. The programs address both hematologic cancers, such as myeloma and AML, and solid tumors, reflecting a long-running research lineage from Professor Grant McFadden’s laboratory. Operationally, the company sits within the pharmaceutical manufacturing space and pursues systemic-oncolytic virotherapy using MYXV. Its efforts rest on two decades of laboratory research led by Professor Grant McFadden, including sequencing of the myxoma virus genome in 1999 and development of multiple engineered constructs that have shown activity in preclinical models. Current programs remain in development for both hematologic cancers and solid tumors, aiming to translate this approach into systemic cancer therapy.
1-888-653-2347 
support@leadiq.com 
